Adalimumab-induced leukocytoclastic vasculitis in a patient with ankylosing spondylitis: A case report.
Alireza KhabbaziMehrzad HajialiloSepideh Tahsini TekantapehSahar Farshchi TabriziAlireza SalehiPublished in: Clinical case reports (2024)
The case discusses a 38-year-old female with a history of ankylosing spondylitis (AS) who presented with skin lesions, including purpuric skin lesions and ischemia of her right foot digits, after initiating treatment with adalimumab. After excluding other potential causes, such as infections and malignancies, the patient received a diagnosis of moderate-sized vascular vasculitis associated with adalimumab use. Discontinuation of adalimumab and treatment with high dose glucocorticoids and intravenous pulse of cyclophosphamide resulted in the resolution of her ischemic lesions. This case underscores the importance of considering drug-related side effects in patients with new skin lesions, particularly in the context of rheumatic diseases such as AS.
Keyphrases
- ankylosing spondylitis
- rheumatoid arthritis
- high dose
- disease activity
- juvenile idiopathic arthritis
- low dose
- soft tissue
- ulcerative colitis
- case report
- blood pressure
- systemic lupus erythematosus
- drug induced
- stem cell transplantation
- combination therapy
- high intensity
- replacement therapy
- climate change
- risk assessment
- oxidative stress
- high glucose